Evaluating Immune Checkpoint Inhibitors for Advanced/Recurrent Endometrial Cancer by MRR Status
Drs Eskander and Lewin discuss the sequencing immune checkpoint inhibitors for women with recurrent endometrial cancer.
Patient Education on Treatment With Immune Checkpoint Inhibitors for Advanced/Recurrent Endometrial Cancer
Sharyn Lewin, MD, FACS, shares how she discusses side effects with patients receiving immune checkpoint inhibitors for advanced/recurrent endometrial cancer.
Approval of Olaparib Combo Impacts SOC in BRCA-Mutant Metastatic CRPC
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
First-Line Treatment Options for Patients With Transplant-Ineligible NDMM
Ashley Rosko, MD, presents the case of a 79-year-old female with transplant-ineligible newly-diagnosed multiple myeloma.
Treatment Considerations for Patients with High-Risk NDMM
Barry Hammer, PA-C, defines high-risk multiple myeloma and explains the treatment adjustments needed for newly-diagnosed patients.
Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment
Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.
Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)
Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.
Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.
Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
Dr Robert Mancini details the bacterial infections usually seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.
Case 3: A 49-Year-Old with R/R MM Treated with Bispecifics and Develops Adenoviral Infection
An expert panel discusses the case of a 49-year-old with relapsed/refractory multiple myeloma treated with a BCMA bispecific antibody who develops adenoviral infection.
Data on Infections and Severe Hypogammaglobulinemia in MM Patients Treated with Anti-BCMA Bispecific Antibodies
Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.
Mechanism of Action of Teclistamab in R/R MM and Data Updates
Melissa Alsina, MD, explains the mechanism of action, data updates and dosing schedule of the BCMA-targeting bispecific antibody teclistamab.
Clinical Pearls on CRS and ICANS Management in Multiple Myeloma
Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.
Managing Toxicities in Patients With MM Treated with ASCT or Novel Therapies
Michael Scordo, MD, gives an overview of a study on dysgeusia seen in patients with multiple myeloma following autologous stem cell transplant or treatment with novel agents.
The Importance of Access to Care for Multiple Myeloma in Community Settings
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Expanding the Treatment Armamentarium in RRMM with Novel Therapies
Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.
Trials Focused on ctDNA in Colorectal Cancer
An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.
Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.
SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer
An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.
CARE Clinic Uses Multidisciplinary Approach For Geriatric Multiple Myeloma
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
